⟷ drag to compare ⟷
aView · LCS
Axial · Slice 147/320 · W:1500 L:-600
LungAI v2.4
~10 mm
Lung-RADS
4X
Very Suspicious
Manual caliper · rounded · category only · ~5 to 10 min
Malignancy Risk
87/100
High Risk
+1.8 mm vs prior
LungAI · Nodule #1
TypeSolid
Size10.2 × 8.4 mm
Volume384 mm³
Density+28 HU
MarginSpiculated
LocationLUL · periph
VDT240 d
Drag to compare
Workflow
Split view
Read time
5 to 10 min / ~2 min
Output
Category + Score
Billable
Standard fees + CPT 0721T · $650
Drag the divider to compare a manual Lung-RADS read with LungAI CADx on the same scan.
AI-Powered Lung Cancer Screening + CADx Diagnostics

Lung-RADS Tells You the Category.
LungAI Tells You the Probability.

The first reimbursed CADx that scores every nodule 0 to 100, with automatic prior-scan comparison, embedded directly inside the CADe viewer your radiologist already uses.

0.96
AUROC on NLST
vs Lung-RADS 0.88
100M
Parameter
Vision Transformer
$650/scan
Reimbursable
under CPT 0721T
The Problem

Up to 4 in 10 Lung Cancer Diagnoses are Wrong

Lung-RADS v2022 depends entirely on human judgement, a manual rule-based scoring system with no AI and no patient personalization.

How Lung-RADS Works Today
1
Manual chart review by radiologist
2
Size-based rules only (no shape or texture AI)
3
Subjective reading, 5-10 min per scan
4
Single snapshot with no longitudinal tracking
5
Result: blanket biopsy referrals or missed cancers
  ~10%
False Negatives
Real cancers missed, caught only when it's too late.
Up to 40%
False Positives
Unnecessary biopsies, procedures, and patient anxiety.
  30%
Inter-Reader Variability
Two radiologists reading the same scan will disagree on the risk category nearly a third of the time.
A radiologist reading 8,000 lung scans per year will incorrectly categorize roughly 2,400 of them, with no AI safety net.
The Solution

AI That Sees What Lung-RADS Misses

LungAI integrates directly into your existing CADe workflow to deliver a continuous 0–100 malignancy risk score per nodule, backed by a 100-million-parameter model trained on 100,000 CT scans and reimbursable under CPT 0721T.

Architecture
Three-Component AI Model
A 3D Vision Transformer nodule encoder, a Sybil-derived whole-scan encoder, and a dense decoder that fuses both with patient demographics and prior scan data to output a per-nodule malignancy probability.
0.96 AUROC
vs Lung-RADS 0.88 on NLST held-out set
Clinical Performance
Fewer Misses. Fewer False Alarms.
At the high-sensitivity threshold, LungAI achieves 94% sensitivity and ~88% specificity — a 60-80% reduction in missed cancers and a 33% reduction in unnecessary biopsies versus standard reads.
94% Sensitivity
~88% Specificity · 1.5–3 min read time
Integration
Zero New Clicks. Built for Your Workflow.
LungAI scores appear directly in your existing CADe viewer. No new workstation, no new login, no IT project. One integration with a CADe partner unlocks their entire hospital network. Post-FDA clearance, every screened patient generates a CPT 0721T billing event at ~$650 per scan.
$650 per scan
CPT 0721T · post-FDA clearance
Pre-FDA Clearance · NLST held-out retrospective study · Results may differ in prospective clinical use
The Platform

One Platform. Full Funnel.

From patient identification to reimbursable diagnosis, Oatmeal Health covers the entire lung cancer screening journey.

1
🧠
Identify
AI Patient Identification

Our AI analyzes EHR data: notes, labs, imaging, billing codes, to predict patients with 20+ pack-year smoking history, even when undocumented. 9x faster than manual chart review with 0.97 AUROC.

2
🩺
Navigate
Care Navigation + SDM Visit

AI navigators help FQHC nurse practitioners conduct shared-decision making visits via telehealth. We help educate patients and drive a 91% scan agreement rate, feeding the diagnostic pipeline.

3
🎯
Diagnose
LungAI CADx: Malignancy Risk

Our 100M-parameter Vision Transformer delivers automated malignancy risk assessments through native integration with PACS/CADe vendors. Nodule-level inference with longitudinal tracking.

Who Benefits

Value for Every Stakeholder

🫁
Patients

Earlier detection increases survival from 9% to 77-92%. Fewer unnecessary biopsies mean less anxiety and fewer complications.

🏥
Providers

New CPT code 0721T generates $650/scan. Monetize existing CTs with no added work, plus improve radiologist accuracy.

🤝
CADe Partners

Billable CADx diagnostic layer with shared revenue: from $5/scan to $110/scan. Competitive differentiation and expanded market footprint.

💰
Health Plans

Avoid $600K+ in late-stage treatment costs. Achieve 4-6x ROI from prevention. Improved outcomes for HEDIS quality metrics.

Trusted Partners

Partnered with Leading Health Systems and FQHCs

Ready to Detect Cancer Earlier?

Whether you’re an FQHC closing care gaps or an imaging center looking to add reimbursable AI services, we make it simple.